About

HR+/HER2- breast cancer grows when hormone receptors and growth signals overactivate the PI3K/mTOR pathway, driving uncontrolled cell division. Gedatolisib blocks both PI3K and mTOR proteins simultaneously, shutting down this growth pathway at multiple points. By targeting these key signaling hubs, the drug may slow tumor progression in cancers that lack PIK3CA mutations but still rely on the pathway.